guidelinebas
manag
asthma
focus
diseas
sever
choos
appropri
medic
therapi
control
symptom
reduc
risk
exacerb
howev
irrespect
asthma
sever
often
despit
optim
medic
therapi
patient
may
experi
acut
exacerb
symptom
loss
diseas
control
asthma
exacerb
commonli
trigger
viral
respiratori
infect
particularli
human
rhinoviru
given
import
event
asthma
morbid
health
care
cost
review
common
incit
factor
asthma
exacerb
approach
prevent
treat
event
despit
optim
guidelinedirect
treatment
irrespect
underli
diseas
sever
patient
asthma
experi
exacerb
caus
accentu
exist
inflammatori
process
loss
diseas
control
asthma
exacerb
major
caus
diseas
morbid
increas
health
care
cost
patient
greater
progress
loss
lung
function
frequenc
exacerb
reduc
alway
fulli
prevent
adequ
inhal
corticosteroid
ic
treatment
combin
icslongact
bagonist
laba
asthma
exacerb
break
standard
treatment
regimen
identifi
atrisk
patient
plan
manag
improv
diseas
control
patient
wellb
asthma
exacerb
remain
major
reason
health
care
util
signific
financi
burden
patient
societi
patient
asthma
exacerb
significantli
higher
total
health
care
cost
versu
dollar
per
person
per
year
asthmaspecif
cost
versu
per
person
per
year
compar
match
patient
without
exacerb
total
expenditur
asthma
estim
billion
per
year
product
loss
due
morbid
mortal
billion
respect
moreov
patient
requir
emerg
depart
ed
visit
hospit
asthma
significantli
increas
risk
futur
exacerb
independ
demograph
clinic
factor
asthma
sever
asthma
control
collect
reflect
ongo
need
develop
better
strategi
prevent
treat
event
common
trigger
exacerb
viral
respiratori
infect
human
rhinoviru
rv
particularli
subtyp
c
frequent
schoolag
children
hospit
admiss
rate
asthma
exacerb
correl
season
increas
rv
infect
septemb
decemb
spring
similar
asthma
hospit
peak
observ
adult
respiratori
virus
also
may
caus
exacerb
influenza
pandem
mortal
admiss
intens
care
unit
infect
frequent
associ
asthma
respiratori
syncyti
viru
frequent
caus
wheez
infant
young
children
may
also
trigger
acut
asthma
adult
particularli
patient
older
year
coronavirus
human
metapneumovirus
parainfluenza
virus
adenovirus
bocavirus
detect
asthma
exacerb
low
frequenc
number
suscept
risk
factor
help
determin
whether
viral
respiratori
infect
caus
exacerb
figur
allergi
defect
antivir
immun
allerg
sensit
risk
factor
wheez
rv
infect
particularli
children
whether
allerg
inflamm
often
found
sensit
increas
suscept
viral
infect
enhanc
abil
provok
inflamm
entir
clear
type
interferon
import
innat
antivir
respons
respiratori
virus
evid
virusinduc
interferon
gener
peripher
blood
mononuclear
cell
plasmacytoid
dendrit
cell
bronchial
epitheli
cell
reduc
patient
allerg
asthma
figur
show
ige
occup
membran
receptor
inhibit
antivir
gener
ifna
plasmacytoid
dendrit
cell
may
increas
suscept
rvinduc
wheez
asthma
exacerb
figur
defici
immun
respons
viral
infect
may
present
type
inflammatori
condit
interferon
product
invers
correl
increas
airway
eosinophilia
level
total
serum
ige
final
use
inhal
ifnb
time
upper
respiratori
infect
reduc
airway
viral
load
improv
clinic
symptom
patient
asthma
bacteri
infect
may
impair
mucociliari
clearanc
increas
mucu
product
lung
may
caus
chronic
lower
airway
inflamm
evid
link
bacteri
infect
acut
asthma
exacerb
limit
howev
respiratori
virus
may
impair
antibacteri
defens
human
alveolar
macrophag
therebi
facilit
emerg
bacteri
infect
chang
microbiom
interrelationship
contribut
exacerb
establish
may
potenti
therapeut
import
prevent
acut
asthma
environment
allergen
provok
asthma
furthermor
children
asthma
sensit
environment
allergen
indoor
allergen
especi
import
underli
asthma
mast
cell
activ
allergen
releas
histamin
prostaglandin
cysteinyl
leukotrien
gener
caus
airway
smooth
muscl
constrict
increas
microvascular
permeabl
mucu
secret
enhanc
inflamm
allerg
sensit
also
associ
diminish
innat
immun
respons
may
suscept
factor
viralinduc
wheez
allergen
associ
inflamm
also
increas
airway
respons
rv
enhanc
loss
asthma
control
mold
sensit
season
increas
parallel
greater
asthma
sever
season
exacerb
patient
sensit
alternaria
alternata
approxim
time
like
asthma
increas
airway
respons
wheez
bronchodil
use
emerg
visit
asthma
exacerb
correl
high
airborn
concentr
mold
final
alternaria
sensit
found
associ
approxim
increas
risk
respiratori
arrest
children
adult
contribut
caus
pollut
tobacco
smoke
ozon
particul
matter
along
occup
exposur
provok
asthma
exacerb
tobacco
smoke
also
implic
develop
persist
wheez
greater
asthma
sever
hospit
ed
visit
asthma
occur
frequent
among
cigarett
smoker
particul
matter
ozon
nitrogen
dioxid
sulfur
dioxid
diesel
exhaust
increas
airway
inflamm
airway
respons
airway
pollut
togeth
viral
infect
may
act
synergist
caus
asthma
exacerb
sever
lower
respiratori
tract
symptom
increas
peak
expiratori
flow
measur
fell
rise
exposur
nitrogen
dioxid
week
respiratori
infect
four
essenti
compon
asthma
manag
includ
patient
educ
monitor
symptom
lung
function
control
trigger
factor
comorbid
condit
pharmacolog
therapi
patient
educ
asthma
decreas
exacerb
improv
control
howev
asthma
sever
vari
differ
among
individu
age
group
essenti
regularli
monitor
effect
asthma
control
guid
necessari
treatment
adjust
expert
panel
report
global
initi
asthma
describ
stepwis
treatment
approach
strategi
reduc
impair
prevent
futur
risk
like
asthma
exacerb
treatment
inhal
corticosteroid
ic
improv
diseas
control
reduc
asthma
exacerb
new
onset
untreat
persist
asthma
lowdos
inhal
budesonid
reduc
asthma
exacerb
almost
ic
poor
control
pauwel
et
al
show
highdos
budesonid
reduc
sever
asthma
exacerb
need
system
corticosteroid
nearli
compar
treatment
lowdos
ic
adult
howev
found
obyrn
et
al
doubl
budesonid
dose
patient
poorli
control
lowdos
ic
also
reduc
exacerb
rate
degre
protect
less
patient
recent
start
ic
find
indic
doserespons
benefit
ic
rel
flat
overal
compar
placebo
shortact
b
agonist
ic
reduc
clinic
relev
exacerb
nearli
ic
also
reduc
exacerb
children
superior
leukotrien
antagonist
montelukast
patient
diminish
asthma
control
quadrupl
recommend
dose
ic
decreas
likelihood
asthma
exacerb
protect
occur
doubl
ic
mainten
howev
benefit
use
increas
ic
time
depend
increas
symptom
need
start
earli
cours
cold
higher
dose
ic
use
preemptiv
onset
respiratori
tract
infect
continu
day
need
oral
corticosteroid
reduc
mechan
ic
prevent
virusinduc
exacerb
beyond
antiinflammatori
activ
poorli
understood
ic
reduc
number
airway
eosinophil
presum
reflect
enhanc
inflamm
respiratori
infect
approxim
asthma
exacerb
associ
increas
airway
eosinophil
cell
reason
target
concept
substanti
studi
show
reduct
airway
eosinophil
significantli
diminish
exacerb
figur
approach
elimin
exacerb
particularli
patient
sever
asthma
furthermor
airway
neutrophil
increas
earli
asthma
exacerb
ic
treatment
effect
cell
altern
approach
need
patient
poorli
control
asthma
histori
prior
asthma
exacerb
combin
budesonid
formoterol
significantli
reduc
asthma
exacerb
compar
ic
alon
icslaba
consist
shown
prevent
exacerb
benefit
icslaba
prevent
exacerb
versu
ic
alon
primarili
seen
patient
requir
higher
dose
ic
thu
suggest
combin
therapi
prevent
exacerb
reserv
patient
sever
diseas
asthma
control
vari
even
face
ongo
ic
laba
treatment
consequ
use
icslaba
combin
mainten
symptom
relief
investig
shown
reduc
exacerb
benefit
also
seen
children
prior
histori
sever
asthma
exacerb
poorli
control
moderatetosever
persist
asthma
despit
use
moder
dose
ic
use
icslaba
mainten
reliev
treatment
restrict
formoterol
quick
onset
action
safeti
profil
doserespons
effect
addit
laba
ic
reduc
asthma
exacerb
remain
unclear
laba
affect
inflamm
icslaba
howev
attenu
allergeninduc
airway
eosinophilia
lung
function
chang
greater
extent
ic
alon
edward
et
al
demonstr
combin
treatment
synergist
suppress
induct
rhinovirusgener
chemokin
bronchial
epitheli
cell
thu
synergist
benefit
ic
laba
airway
eosinophil
inflamm
might
explain
greater
reduct
exacerb
altern
earli
use
icslaba
relief
symptom
might
simpli
deliv
addit
ic
airway
earli
cours
emerg
exacerb
antileukotrien
reduc
asthma
exacerb
children
adult
montelukast
reduc
asthma
exacerb
rv
infect
occur
return
school
septemb
systemat
review
metaanalysi
compar
placebo
leukotrien
modifiersreceptor
antagonist
lower
exacerb
rate
inferior
ic
ad
montelukast
inhal
budesonid
effect
doubl
dose
inhal
budesonid
differ
exacerb
rate
asthma
free
day
anticholinerg
tiotropium
reduc
frequenc
asthma
exacerb
fdaapprov
longterm
mainten
treatment
patient
year
age
older
persist
asthma
uncontrol
ic
plu
one
control
replic
trial
total
adult
patient
sever
asthma
use
icslaba
ad
tiotropium
mcg
increas
time
first
exacerb
day
placebo
reduc
exacerb
figur
systemat
review
random
placebocontrol
trial
tiotropium
decreas
rate
exacerb
improv
asthma
control
patient
moder
symptomat
asthma
alreadi
receiv
mediumtohigh
dose
ic
icslaba
studi
children
age
year
demonstr
improv
forc
expiratori
volum
second
fev
reduct
exacerb
like
due
short
durat
studi
howev
given
decreas
fev
forc
vital
capac
ratio
associ
increas
risk
exacerb
improv
fev
tiotropium
may
associ
reduc
exacerb
children
benefit
environment
control
measur
prevent
exacerb
limit
perhap
environment
intervent
usual
focu
singl
allergen
dust
mite
environment
tobacco
smoke
limit
approach
effect
seen
asthma
morbid
howev
innerc
asthma
studi
evalu
effect
multifacet
homebas
environment
intervent
use
remedi
exposur
dust
mite
passiv
smoke
cockroach
pet
rodent
mold
tailor
child
skintest
sensit
profil
environment
exposur
intervent
group
report
significantli
fewer
symptom
asthma
intervent
year
interestingli
followup
year
well
figur
significantli
fewer
unschedul
asthmarel
visit
ed
clinic
intervent
group
p
correl
reduct
level
cockroach
allergen
bedroom
floor
asthmarel
morbid
particularli
strong
activ
intervent
although
difficult
gener
result
children
asthma
reduct
continu
exposur
environment
allergen
irrit
like
present
home
innerc
patient
risk
reduct
asthma
exacerb
hazard
ratio
p
pool
analysi
tiotropium
group
reproduc
permiss
kerstjen
et
al
j
allergi
clin
immunol
pract
volum
number
asthma
may
indic
need
comprehens
intervent
omalizumab
approv
use
patient
year
age
older
allergi
uncontrol
persist
asthma
despit
moderatetohigh
dose
ic
omalizumab
human
monoclon
antibodi
direct
ige
reduc
risk
asthma
exacerb
allerg
asthmat
patient
omalizumab
reduc
asthma
exacerb
given
ic
shorten
durat
exacerb
adult
children
patient
asthma
allergi
diminish
interferon
respons
vitro
challeng
respiratori
virus
reduct
relat
ige
studi
innerc
children
omalizumab
reduc
season
exacerb
fall
spring
without
alter
rate
infect
respiratori
virus
suggest
omalizumab
may
prevent
viral
infect
rather
modifi
consequ
infect
teach
et
al
show
omalizumab
improv
antivir
defens
increas
releas
ifna
peripher
blood
mononuclear
cell
rv
stimul
subject
greater
restor
ifn
respons
fewer
exacerb
occur
figur
thu
addit
antiinflammatori
effect
omalizumab
restor
antivir
activ
may
prevent
exacerb
select
patient
like
benefit
omalizumab
difficult
post
hoc
analysi
patient
elev
level
fraction
exhal
nitric
oxid
blood
eosinophil
serum
periostin
like
reflect
greater
inflamm
greater
likelihood
benefit
omalizumab
two
monoclon
antibodi
mepolizumab
reslizumab
approv
mainten
therapi
patient
uncontrol
persist
eosinophil
asthma
exacerb
phenotyp
despit
highdos
ic
contribut
airway
eosinophil
inflamm
approxim
patient
difficulttocontrol
asthma
persist
airway
eosinophilia
despit
treatment
highdos
ic
although
elev
sputum
eosinophil
count
predict
risk
asthma
exacerb
use
sputum
routin
measur
impract
clinic
practic
price
et
al
found
relationship
intens
peripher
blood
eosinophilia
asthmarel
outcom
patient
asthma
blood
eosinophil
count
greater
cellsml
experi
frequent
sever
exacerb
serv
conveni
biomark
therapi
mepolizumab
given
subcutan
reduc
exacerb
approxim
patient
sever
asthma
blood
eosinophil
count
cellsml
greater
figur
fdaapprov
addon
mainten
treatment
sever
asthma
patient
year
age
older
although
clinic
trial
data
suggest
efficaci
requir
absolut
eosinophil
count
least
cellsml
nation
institut
health
care
excel
recommend
threshold
cellsml
reslizumab
also
fdaapprov
addon
mainten
therapi
sever
asthma
patient
year
older
eosinophil
count
cellsml
higher
clinic
trial
intraven
reslizumab
reduc
asthma
exacerb
approxim
rv
infect
lead
gener
increas
airway
eosinophil
correl
exacerb
probabl
relationship
provid
probabl
explan
mab
treatment
reduc
asthma
exacerb
biolog
prevent
asthma
exacerb
studi
despit
optim
mainten
therapi
asthma
control
exacerb
occur
therefor
earli
recognit
intervent
import
success
stabil
asthma
limit
number
treatment
current
avail
allevi
asthma
exacerb
evid
support
use
limit
inhal
nebul
shortact
b
agonist
saba
albuterol
levalbuterol
resolv
acut
symptom
asthma
initi
use
everi
minut
first
hour
acut
asthma
levalbuterol
renantiom
albuterol
albuterol
equival
data
conflict
whether
continu
nebul
saba
superior
intermitt
nebul
sever
asthma
exacerb
continu
nebul
consid
base
evid
reduc
admiss
improv
pulmonari
function
saba
provid
symptomat
relief
effect
airway
inflamm
sustain
benefit
ad
ipratropium
bromid
inhal
saba
sever
exacerb
decreas
rate
hospit
shorten
ed
stay
patient
sever
moderatetosever
asthma
exacerb
benefit
ipratropium
bromid
saba
therapi
seen
primarili
sever
asthma
exacerb
corticosteroid
underli
compon
exacerb
increas
airway
inflamm
numer
studi
evalu
ic
oral
corticosteroid
oc
asthma
exacerb
evid
efficaci
remain
limit
moreov
ic
often
prevent
exacerb
unlik
increas
inflamm
exacerb
fulli
respons
corticosteroid
nonetheless
use
reason
expect
first
step
inhal
corticosteroid
administr
highdos
ic
asthma
exacerb
reserv
patient
mild
intermitt
asthma
unabl
toler
oc
side
effect
diabet
psychiatr
effect
systemat
review
analyz
studi
compar
efficaci
ic
placebo
acut
asthma
exacerb
found
ic
appear
superior
placebo
especi
given
high
dose
mg
budesonid
fluticason
howev
patient
studi
heterogen
sever
ic
dose
administr
frequenc
outcom
measur
role
ic
asthma
exacerb
remain
establish
comparison
ic
system
corticosteroid
also
conflict
oc
superior
ic
reduc
hospit
admiss
rate
studi
other
show
superior
ic
systemat
review
trial
conclud
benefit
addit
ic
system
corticosteroid
reduc
relaps
rate
acut
asthma
present
insuffici
evid
exist
support
use
ic
rather
oc
exacerb
system
corticosteroid
earli
administr
system
corticosteroid
treatment
acut
exacerb
standard
guidelin
manag
benefici
effect
system
corticosteroid
usual
delay
approxim
hour
system
glucocorticoid
acceler
rate
improv
persist
airflow
obstruct
exist
despit
bronchodil
treatment
howev
evidencebas
evalu
report
neither
improv
airflow
obstruct
reduct
hospit
rate
system
corticosteroid
contrast
systemat
review
row
et
al
conclud
use
system
corticosteroid
adult
children
reduc
rate
hospit
admiss
ed
treatment
set
especi
patient
sever
asthma
current
receiv
corticosteroid
optim
dose
system
corticosteroid
asthma
exacerb
also
remain
convincingli
establish
dose
mgkg
mgday
add
benefit
improv
pulmonari
function
rate
hospit
admiss
length
hospit
stay
furthermor
differ
found
oral
intraven
administr
compar
dose
prescrib
short
cours
oral
corticosteroid
ed
treatment
acut
asthma
exacerb
reduc
rate
relaps
although
durat
therapi
fulli
establish
cours
longer
day
provid
addit
benefit
also
benefit
use
dose
taper
fixeddos
regimen
stop
difficulti
howev
aris
assess
approach
treat
exacerb
patient
alreadi
take
system
corticosteroid
optim
exacerb
treatment
strategi
patient
popul
remain
undefin
reflect
need
target
therapi
singl
dose
benralizumab
receptor
monoclon
antibodi
reduc
rate
sever
subsequ
exacerb
given
time
initi
exacerb
thu
biolog
therapi
may
also
benefici
acut
treatment
asthma
exacerb
prevent
subsequ
event
asthma
exacerb
prevent
ic
icslaba
biolog
patient
exacerb
frequent
patient
sever
diseas
prevent
strategi
biolog
antiig
seen
exacerb
occur
system
corticosteroid
remain
primari
intervent
bronchodil
therapi
effect
evid
benefit
limit
prevent
exacerb
remain
major
unmet
need
asthma
manag
improv
understand
pathogenesi
asthma
exacerb
like
lead
new
strategi
prevent
treat
asthma
exacerb
